

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.



深圳市海王英特龍生物技術股份有限公司
SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED*
(a joint stock limited company incorporated in the People's Republic of China)
(Stock Code: 8329)

REVISED NOTICE OF EXTRAORDINARY GENERAL MEETING

Reference is made to (i) the notice of extraordinary general meeting of 深圳市海王英特龍生物技術股份有限公司 (Shenzhen Neptunus Interlong Bio-technique Company Limited*) (the “**Company**”) dated 12 December 2022 (the “**Original Notice**”) in relation to the New Neptunus Group Sales Framework Agreement (as defined below) and all transactions contemplated thereunder and the proposed amendments to the existing articles of association of the Company, and (ii) the announcement of the Company dated 30 December 2022 in relation to the delay in depatch of circular and change of EGM date (the “**Announcement**”). Pursuant to the Announcement, the date of EGM has been changed to 31 January 2023. Unless defined otherwise herein, capitalized terms used in this notice shall have the same meanings as defined in the Original Notice.

REVISED NOTICE IS HEREBY GIVEN that an extraordinary general meeting (the “**EGM**”) of the Company will be held at 10:00 a.m. on Tuesday, 31 January 2023 at Meeting Room, 24th Floor, Neptunus Yinhe Technology Mansion, 1 Keji Middle 3rd Road, Nanshan District, Shenzhen, Guangdong Province, the People's Republic of China (the “**PRC**”), for the purpose of considering and, if thought fit, passing, with or without modifications, the following resolutions.

ORDINARY RESOLUTION

1. “**THAT**

- (a) the form and substance of the sales framework agreement (the “**New Neptunus Group Sales Framework Agreement**”) dated 1 December 2022 entered into between the Company and 深圳海王集團股份有限公司 (Shenzhen Neptunus Group Company Limited*) pursuant to which the Group agreed to sell certain self-manufactured or distributed products including certain pharmaceutical products, healthcare food products and medical devices to 深圳海王集團股份有限公司 (Shenzhen Neptunus Group Company Limited*) and its subsidiaries (but excluding the

Group) (a copy of the New Neptunus Group Sales Framework Agreement has been produced to the meeting and marked “A” and initialled by the chairman of the meeting for identification purpose) and all the transactions contemplated thereby be and are hereby approved, confirmed and ratified;

- (b) the proposed sales caps under the New Neptunus Group Sales Framework Agreement for each of the three years ending 31 December 2023, 2024 and 2025 be and is hereby confirmed and approved; and
- (c) any one director of the Company (the “**Director**”) be and are hereby authorised to do all such acts and things, negotiate, approve, sign, initial, ratify and/or execute all documents which may in the opinion of the Director may consider necessary, appropriate, desirable or expedient to give effect to or in connection with the New Neptunus Group Sales Framework Agreement or any transactions contemplated thereunder and to agree to such variation, amendments or waiver or matters relating thereto (including any variation, amendments or waiver of such documents, which are not fundamentally different from those as provided under the New Neptunus Group Sales Framework Agreement) as are, in the opinion of the Director, in the interest of the Company and its shareholders as a whole.”

SPECIAL RESOLUTION

- 2. “**THAT** the proposed amendments to the articles and association of the Company be and are hereby approved.”

Please refer to the Company’s announcement dated 1 December 2022 for details of the New Neptunus Group Sales Framework Agreement and details of the proposed amendments to the articles of association of the Company. In accordance with the requirements under Rule 20.44(1) and Rule 25.34A of the Rules Governing the Listing of Securities on GEM of the Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”) and the PRC Company Law, the Company will deliver a circular containing details of the New Neptunus Group Sales Framework Agreement and the transactions contemplated thereunder and the details of the proposed amendments to the articles of association to the Shareholders as soon as possible.

By order of the Board
Shenzhen Neptunus Interlong Bio-technique Company Limited*
Zhang Feng
Chairman

Shenzhen, the PRC, 11 January 2023

Registered office:
Suite 2103, 21st Floor
Neptunus Yinhe Technology Mansion,
1 Keji Middle 3rd Road,
Yuehai Sub-district,
Nanshan District,
Shenzhen,
Guangdong Province,
PRC

Principal place of business in Hong Kong:
18th Floor, United Centre,
95 Queensway,
Admiralty,
Hong Kong

* *For identification purpose only*

Notes:

- (1) Shareholders should note that a revised form of proxy issued to the shareholders separately supersedes and replaces the form of proxy for the EGM despatched on 13 December 2022 (the “**Original Proxy Form**”) and that the Original Proxy Form is void and invalid. SHAREHOLDERS WHO HAVE SIGNED AND RETURNED THE ORIGINAL PROXY FORM SHOULD COMPLETE AND RETURN THE REVISED FORM OF PROXY IN ACCORDANCE WITH THE INSTRUCTIONS PROVIDED THEREIN.
- (2) A shareholder of the Company (the “**Shareholder**”) entitled to attend and vote at the EGM is entitled to appoint one or more proxies to attend and vote instead of him. A proxy need not be a Shareholder. In the case of joint holders of shares of the Company (the “**Shares**”), any one of such joint holders may sign the revised form of proxy. However, if more than one of such joint holders are present at the EGM, whether personally or by proxy, that one of the joint Shareholders so present whose name stands first in the register of Shareholders in respect of such Shares shall alone be entitled to vote in respect thereof.
- (3) In order to be valid, the revised form of proxy together with a power of attorney or other authority (if any) under which it is signed or the notarised copy of such power of attorney or authority must be lodged, in the case of holders of H shares of the Company (the “**H Shares**”), with the Company’s H share registrar in Hong Kong, Tricor Investor Services Limited (the “**Company’s H Share Registrar**”), at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, and in the case of holders of domestic shares of the Company (the “**Domestic Shares**”), to the registered address of the Company at Suite 2103, 21st Floor, Neptunus Yinhe Technology Mansion, 1 Keji Middle 3rd Road, Yuehai Sub-district, Nanshan District, Shenzhen, Guangdong Province, the PRC no later than 24 hours before the time appointed for the holding of the EGM (i.e. not later than 10:00 a.m. on Monday, 30 January 2023) or any adjournment thereof (as the case may be).
- (4) The Shareholders or their proxies will be required to produce proof of their identities (and a copy of the form of the revised proxy in case of proxies) when attending the EGM.
- (5) To ascertain the Shareholders’ entitlement to attend and vote at the Meeting, the register of Shareholders of the Company will be closed from Tuesday, 10 January 2023 to Tuesday, 31 January 2023, both days inclusive, during which period no transfer of Shares will be effected. As regards holders of H Shares, in order to qualify for attendance at the EGM, all transfers of H Shares accompanied by the relevant share certificates must be lodged with the Company’s H Share Registrar, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong no later than 4:30 p.m. on Monday, 9 January 2023).

- (6) The EGM is expected to last for no more than a day. The Shareholders or their proxies attending the EGM shall bear their own traveling, accommodation and meal expenses.
- (7) Voting at the EGM will be conducted by way of poll.
- (8) For any enquiries about this notice, please contact the contact person of general meetings, Mr. Huang Jian Bo, at +86 755 2640 1275.
- (9) References to time and dates in this notice are to Hong Kong time and dates.
- (10) Taking into account of the recent development of the epidemic caused by novel coronavirus pneumonia (COVID-19), Shareholders are strongly encouraged not to attend the EGM in person and to vote by way of proxy instead. The Company will implement the following prevention and control measures at the EGM against the epidemic to protect the Shareholders from the risk of infection:
 - Compulsory body temperature check and health declarations will be conducted for every Shareholder or proxy at the entrance of the venue. Any person with a body temperature of over 37.5 degrees Celsius will not be admitted to the venue;
 - Every Shareholder or proxy is required to wear surgical facial mask throughout the meeting; and
 - No distribution of corporate gifts and no refreshments will be served.

Furthermore, the Company wishes to advise the Shareholders, particularly the Shareholders who are subject to quarantine in relation to COVID-19, that they may appoint any person or the chairman of the EGM as a proxy to vote on the resolutions, instead of attending the EGM in person.

As at the date of this notice, the executive Directors are Mr. Zhang Feng and Mr. Huang Jian Bo; the non-executive Directors are Mr. Zhang Yi Fei, Ms. Yu Lin, Mr. Shen Da Kai and Mr. Jin Rui; and the independent non-executive Directors are Mr. Yick Wing Fat, Simon, Mr. Poon Ka Yeung and Mr. Zhang Jian Zhou.

This notice, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this notice is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this notice misleading.

This notice will remain on the “Latest Company Announcements” page of the GEM website at www.hkgem.com for at least 7 days from its date of publication and on the Company’s website at www.interlong.com.